期刊文献+

肺鳞癌靶向治疗研究现状 被引量:4

Research Status on Targeted Therapy for Squamous Cell Lung Cancer
下载PDF
导出
摘要 随着肺癌驱动基因研究的逐步深入,肺癌靶向治疗已取得较大进展。与肺腺癌相比,肺鳞癌的靶向治疗进展明显滞后。对肺腺癌临床疗效确切的靶向药物,如:表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)、棘皮类微管相关样蛋白-4(echinodern microtubule-associatedprotein-like 4,EML4)-间变型淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因抑制剂等,均对肺鳞癌疗效欠佳,目前肺鳞癌缺少有效的靶向治疗药物。因此,迫切需要对肺鳞癌的驱动基因和靶向治疗进行更深入的研究。本文将对肺鳞癌靶向治疗的研究现状作一综述。 With the research of driver mutations, targeted therapy for lung cancer has made a great progress. Com-pared with lung adenocarcinoma, treatment of squamous cell lung cancer (SCC) has been far behind. While targeted therapies have improved outcomes for patients with lung adenocarcinoma, such as EGFR-TKIs, EML4-ALK inhibitors, molecularly tar-geted drugs are poorly active for SCC. SCC currently lacks therapeutically exploitable genetic alterations. hTese observations emphasize the need for new driver mutations and“druggable”targets in SCC patients. Combining with the research in recent years, this review will discuss the research status in targeted therapy for SCC.
出处 《中国肺癌杂志》 CAS 北大核心 2013年第10期559-563,共5页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 鳞癌 靶向治疗 Lung neoplasms Squamous cell carcinoma Targeted therapy
  • 相关文献

参考文献35

  • 1Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification as- sociates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med, 201 O, 2 (62): 62ra93.
  • 2Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One, 2011, 6(6): e20351.
  • 3WolfJ. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors [abstract]. In: Proceedings of the 103- Annual Meeting of the Ameri-can Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA) : AACR; 2012. Abstract nr LB- 122.
  • 4Ford CE, Lau SK, Zhu COL et al. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer, 2007, 96(5): 808-814.
  • 5Davies Hj Hunter C, Smith Rj et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res, 2005, 65 (17): 7591-7595.
  • 6Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov- 2011, 1(1): 78-89.
  • 7Zito CK, Jilaveanu LB, Anagnostou V, et al. Multi-level targeting of the phos- phatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS Onej 2012, 7(2): e31331.
  • 8Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer, 2006, 54(2): 209-215.
  • 9Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplifica- tion in human lung cancer. Pathol Int, 2007, 57(10): 664-671.
  • 10ji M, Guan H, Gao C, et al. Highly frequent promoter methylation and PIK- 3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer, 2011, 11: 147.

同被引文献74

  • 1余彩玲.中心静脉导管胸腔闭式引流联合顺铂胸腔灌注对癌性胸水的治疗应用[J].中国医药导报,2010,7(23):21-23. 被引量:3
  • 2陆舜,虞永峰,李子明.肺癌分子靶向治疗进展[J].中华肿瘤杂志,2005,27(11):701-704. 被引量:5
  • 3董强刚,韩宝惠,黄进肃,杨立民,黄建,赵春英,卢丽琴.176例非小细胞肺癌的EGFR基因突变分析[J].中华肿瘤杂志,2006,28(9):686-690. 被引量:53
  • 4余宗阳,欧阳学农,杜建,季天海,李捷.非小细胞肺癌中胰岛素样生长因子-1受体的表达[J].福州总医院学报,2006,13(4):202-204. 被引量:1
  • 5张彩云,曹金红.妇科恶性肿瘤介入化疗病人的护理[J].护理研究(中旬版),2007,21(10):2690-2690. 被引量:11
  • 6Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous nonsmall cell lung cancer. Drugs, 2014, 74(4): 403-413.
  • 7Mitsudomi T, Morita S, Yatabe Y, ei al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).J Clin Oncol, 2012, 30 (Suppl). Abstr 7521.
  • 8Mok TS, Wu YL, Yu cj, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.J Clin Oncol, 2012, 30(Supp!): Abstr 7520.
  • 9Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with nonsmall cell lung cancer. Clin Cancer Res, 2005, 1l(12): 4289-4294.
  • 10Lai Y, Zhang Z, LiJ, et al. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. IntJ Mol Sci, 2013, 14(12): 24549-24559.

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部